Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV Radiation

This study has been completed.
Sponsor:
Collaborator:
Nestlé
Information provided by:
L'Oreal
ClinicalTrials.gov Identifier:
NCT00351689
First received: July 12, 2006
Last updated: October 2, 2012
Last verified: October 2012
  Purpose

A probiotic bacterial strain was tested in a randomized, double blind , placebo controlled clinical trial with 54 healthy male volunteers. Half the volunteers received the dietary supplement the other half placebo during 6 weeks prior to exposure to solar-simulated UV irradition (2x1,5MED). Blister roofs and skin biopsies were recovered 1, 4 and 10 days after UV exposure from unirradiated and irradiated skin and used for immunohistochemical analysis and mixed epidermal cell lymphocyte reaction


Condition Intervention Phase
Photobiology
Behavioral: dietary supplement
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV Radiation

Resource links provided by NLM:


Further study details as provided by L'Oreal:

Primary Outcome Measures:
  • Evaluation of food supplement effect on the functions of epidermal cells after UV radiation exposure.

Secondary Outcome Measures:
  • Qualitative analysis (activation and/or maturation status) of cutaneous Langerhans cells and macrophages and analysis of their location and Evaluation of the erythema, pigmentation after UV exposure, Evaluation of safety.

Estimated Enrollment: 50
Study Start Date: January 2004
Estimated Study Completion Date: July 2004
Detailed Description:

Langerhans cells (LC), the dendritic cells (DC) from epidermis, constitute the first line of immune defense against environmental attacks. Under steady state conditions, LC turnover is very low. The LCs reside in the epidermis in an immature state and can be distinguished from other epidermal cells by their surface expression of HLA-DR, CD1a and langerin. Upon stimulation by inflammatory mediators LCs are activated and acquire CCR7 expression, the chemokine receptor for CCL21 that mediates their migration to lymph nodes. Moreover, activated LCs display a mature phenotype characterized by increased expression of co-stimulatory molecules and acquisition of maturation markers that facilitate their interaction with T-cells and aid in the elicitation of the immune response.

It has long been known that, in addition to being carcinogenic via DNA damage and mutations, solar UV radiation induces local and systemic immune suppression which represents a major risk for skin cancer induction and progression in sun-exposed areas. The process is mostly related to direct LC damage through induction of apoptosis and impairment of antigen-presenting function. Moreover, UV radiation elicits an inflammatory response and subsequent recruitment of immune cells, including CD36+ monocytic cells. These cells colonize the epidermis in the days following UV exposure and are the major source of immunosuppressive cytokines such as IL-10. All these mechanisms ultimately lead to impaired cell-mediated reactions and establishment of immune tolerance.

Nutritional intervention, particularly with dietary antioxidants and vitamins, has been proposed to protect against UV-induced skin damage and to a certain extent skin cancer occurrence. In recent years, there has been an increasing interest for probiotics, defined as live microorganisms which, when consumed in adequate amounts, confer a health benefit upon the host. Particular focus has been on species of lactic acid bacteria including Lactobacilli and Bifidobacteria that are part of the natural human intestinal microbiota. Indeed, it is well documented that the endogenous intestinal microbiota plays a crucial role in immune maturation, gut integrity and defense against pathogens. Recently, it has been shown that some probiotic bacteria possess the ability to modulate the immune system at both the local and systemic levels and thereby improve immune defense mechanisms and/or down-regulate immune disorders such as intestinal inflammations or allergies.

The Probiotic used as the dietary supplement, was isolated from healthy adult microbiota and was shown to have a strong anti-pathogenic activity against a wide range of entero-pathogens. Furthermore, a pre-clinical study demonstrated that it can maintain the epidermal LC density.

Here, we analyzed, in a randomized double blind, placebo controlled, clinical trial, whether this dietary supplement could also modulate the cutaneous immune homeostasis after solar-simulated UV exposure in humans.For this purpose, we analyzed whether this dietary supplement could interfere with LC allostimulatory function and activation/maturation phenotypic status of skin DC, after solar-simulated UV irradiation.

  Eligibility

Ages Eligible for Study:   20 Years to 40 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy subject
  • Gender: male.
  • Age: greater than 20 years and less than 40 years.
  • Phototype: II or III.
  • Subject having freely given his informed written consent.
  • Cooperative subject, aware of the necessity for and duration of the controls, suggesting complete compliance with the protocol set up by Laboratoire DERMSCAN.
  • Subject with Social Security coverage.
  • A priori, a low fermented milk product consumer (less than 125 g/d) who, during the study, agrees not to eat fermented milk products containing live bacteria (yogurt, cream cheese, fermented dairy products, unpasteurized cheese, etc.).

Exclusion Criteria:

  • Subject deprived of freedom by a court or administrative order.
  • Minor or major protected by law.
  • Subject residing in a health or social care establishment.
  • Patient in an emergency setting.
  • Subject presenting with skin disease on the test zones.
  • Subject presenting with a stable or progressive serious disease (investigator's assessment).
  • Immunocompromised subject.
  • Subject allergic to one of the constituents of the test products or to xylocaine.
  • Subject with a history of allergy to solar or UV radiation.
  • Immoderate use of alcohol (more than 2 glasses of wine daily or more than 1 glass of spirits daily).
  • Immoderate smoker (more than 6 cigarettes/day).
  • Subject exposed to the sun or UV radiation in the last 3 months (facial exposure was authorized with use of a total-block sunscreen and sunglasses).
  • Subject with cardiovascular or circulatory disease history.
  • Subject with a history of skin cancer, malignant melanoma.
  • Subject with a history of intestinal surgery.
  • Antibiotic, corticosteroid, non-steroidal anti-inflammatory or immunosuppressant intake.
  • Strenuous sports (> 5 hours per week) or naturism.
  • Subject having taken a course of mineral supplements or vitamins in the 3 months preceding study initiation.
  • Vegetarian or vegan diet.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00351689

Locations
France
Dermscan
Lyon Villeurbane, France, 69 603
Sponsors and Collaborators
L'Oreal
Nestlé
Investigators
Study Director: AUDREY GUENICHE, PhD L'Oreal
Study Director: TIMO BUETLER, PhD Nestlé
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00351689     History of Changes
Other Study ID Numbers: 1030740
Study First Received: July 12, 2006
Last Updated: October 2, 2012
Health Authority: France: Ministry of Health

Keywords provided by L'Oreal:
Probiotic bacteria
cutaneous immune homeostasis
UV radiation
dietary supplement

ClinicalTrials.gov processed this record on October 20, 2014